Skip navigation

A trial looking at capecitabine with or without bevacizumab for colorectal cancer (QUASAR 2)

Please note this trial is no longer recruiting patients.

This trial is comparing capecitabine and bevacizumab with capecitabine alone for bowel (colorectal) cancer.

Surgery is a common treatment for bowel cancer. And doctors often treat colorectal cancer with chemotherapy after surgery to help stop the cancer coming back. Two drugs commonly used are 5FU and capecitabine (Xeloda). Capecitabine is similar to 5FU but is a tablet rather than an injection.

Doctors think that the combination of capecitabine and bevacizumab (Avastin) may be even better at stopping the cancer coming back. But they are not sure yet how well this new combination will work. Bevacizumab is type of biological therapy called a monoclonal antibody.

In this trial, some patients have capecitabine alone. And some have capecitabine and bevacizumab. The aim of the trial is to find out which is best at stopping colorectal cancer coming back after surgery. And to find out more about the side effects.

Recruitment

Start 12/04/2005
End 30/09/2010

Phase

Phase 3

Who can enter

You can enter this trial if you

  • Have stage 3 colorectal cancer or stage 2 colorectal cancer, which your doctors think has a high risk of spreading to another part of the body
  • Had surgery to remove all of your colorectal cancer between 4 and 10 weeks ago
  • Are well enough for treatment (performance status 0 or 1)
  • Have satisfactory blood test results
  • Are prepared to use effective contraception if there is any chance either you or your partner could become pregnant
  • Are at least 18 years old

You cannot enter this trial if you

  • Have had chemotherapy, immunotherapy or radiotherapy before
  • Have had any other trial treatment in the last 4 weeks
  • Regularly take medication to thin your blood (anti coagulants) or have blood that doesn’t clot quickly enough
  • Are taking the anti viral drugs sorivudine or brivudine
  • Have chronic inflammatory bowel disease, bowel obstruction, a stomach ulcer or any other condition that means you are not able to take or absorb tablets
  • Have heart disease, or have had a stroke or heart attack in the last year
  • Have had any other cancer, apart from non melanoma skin cancer or carcinoma in situ of the cervix
  • Are pregnant or breastfeeding

Trial design

This is a phase 3 trial. It will recruit 2,240 patients into 2 groups. The trial is randomised. The people taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in.

If you are in group 1, you will have capecitabine. You take capecitabine tablets twice a day (12 hours apart) for 2 weeks out of every 3. Then you don’t take any in the 3rd week. Each 3 week block is one cycle of chemotherapy. You have 8 cycles over about 6 months altogether.

If you are in group 2, you will have capecitabine and bevacizumab. You take capecitabine tablets as for group 1 above. On the first day of each 3 week cycle you have bevacizumab through a drip into a vein. This takes about an hour and a half for first dose, about an hour for the second dose, and about half an hour for each dose after that.

You have 8 cycles of capecitabine over about 6 months. But you have 16 cycles of bevacizumab, so treatment will take about 12 months altogether.

Hospital visits

You will see the doctors and have some blood tests and a urine test before you start the trial.

If you are in group 1 you will go to hospital once every 3 weeks to see the doctors and pick up your capecitabine tablets.

If you are in group 2 you go to the hospital once every 3 weeks to pick up your capecitabine tablets and to have the bevacizumab injection. You will have blood tests and urine test before each dose of bevacizumab.

After you finish treatment you will see the doctors every 6 months for a year and then once a year after that.

Side effects

The most common side effects of capecitabine are

The most common side effects of bevacizumab are

There is more information about capecitabine (Xeloda) and bevacizumab (Avastin) on CancerHelp UK.

Location of trial

CLOSED

For more information

The Information Nurses
Cancer Research UK
Angel Building
407 St John Street
London
EC1V 4AD

Tel: 0808 800 4040
Email: cancer.info@cancer.org.uk

Please note: we cannot help you to join a specific trial. Unless we state otherwise in this trial summary, you must go through your own doctor.

Chief Investigator

Dr David Kerr

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
National Cancer Research Network (NCRN)
Roche
University of Oxford